Randomized, Placebo-controlled, Double-blind, Parallel Group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses of BAY2328065 Including the Relative Bioavailability Between Solution and Tablet Formulation and the Effect of Food on the Pharmacokinetics of BAY2328065 in Healthy Men
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Mar 2018
At a glance
- Drugs BAY-2328065 (Primary) ; BAY-2328065 (Primary)
- Indications Endometriosis
- Focus Adverse reactions
- Sponsors Bayer
- 09 Mar 2018 Planned number of patients changed from 80 to 88.
- 06 Mar 2018 Planned initiation date changed from 15 Feb 2018 to 10 Apr 2018.
- 13 Feb 2018 New trial record